1. Açık Erişim@BUU
  2. İndeksli Yayınlar
  3. Web of Science
Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/24297
Tüm üstveri kaydı
Dublin Core AlanıDeğerDil
dc.date.accessioned2022-01-26T06:44:26Z-
dc.date.available2022-01-26T06:44:26Z-
dc.date.issued2009-11-
dc.identifier.citationEker, S. S. vd. (2009). "The potential relationship between QTc interval prolongation and ziprasidone treatment: Three cases". Journal of Psychopharmacology, 23(8), 993-996.en_US
dc.identifier.issn0269-8811-
dc.identifier.urihttps://doi.org/10.1177/0269881108093843-
dc.identifier.urihttps://journals.sagepub.com/doi/10.1177/0269881108093843-
dc.identifier.urihttp://hdl.handle.net/11452/24297-
dc.description.abstractQTc interval prolongation may appear as a consequence of both typical and atypical antipsychotic treatments. Ziprasidone, which is effective in treating schizophrenia, is associated with QTc prolongation. Although the prolongation of QTc with ziprasidone treatment is often pronounced, there is a scarce number of cases reported about the relationship between ziprasidone and QTc prolongation. Of the three cases presented in this case series, two cases showed values exceeding 0.50 s with ziprasidone treatment.en_US
dc.language.isoenen_US
dc.publisherSage Publicationsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntipsychoticen_US
dc.subjectQTc prolongationen_US
dc.subjectZiprasidoneen_US
dc.subjectTorsade-de-pointesen_US
dc.subjectSchizoaffective disorderen_US
dc.subjectAntipsychotic-drugsen_US
dc.subjectAcute exacerbationen_US
dc.subjectDouble-blinden_US
dc.subject160 mg/dayen_US
dc.subjectSchizophreniaen_US
dc.subjectSafetyen_US
dc.subjectHaloperidolen_US
dc.subjectManagementen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectPsychiatryen_US
dc.subject.meshAdulten_US
dc.subject.meshAntipsychotic agentsen_US
dc.subject.meshElectrocardiographyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPiperazinesen_US
dc.subject.meshThiazolesen_US
dc.titleThe potential relationship between QTc interval prolongation and ziprasidone treatment: Three casesen_US
dc.typeArticleen_US
dc.identifier.wos000271496000018tr_TR
dc.identifier.scopus2-s2.0-70449419969tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.identifier.startpage993tr_TR
dc.identifier.endpage996tr_TR
dc.identifier.volume23tr_TR
dc.identifier.issue8tr_TR
dc.relation.journalJournal of Psychopharmacologyen_US
dc.contributor.buuauthorEker, Salih Saygın-
dc.contributor.buuauthorSarandol, Aslı-
dc.contributor.buuauthorAkkaya, Cengiz-
dc.contributor.buuauthorSivrioğlu, Enver Yusuf-
dc.contributor.buuauthorKırlı, Selçuk-
dc.contributor.researcheridQ-9477-2019tr_TR
dc.identifier.pubmed18635710tr_TR
dc.subject.wosClinical neurologyen_US
dc.subject.wosNeurosciencesen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubmeden_US
dc.wos.quartileQ1en_US
dc.wos.quartileQ2en_US
dc.contributor.scopusid14019347700tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid14062563200tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.subject.scopusNeuroleptic Agent; Prolongation; Ziprasidoneen_US
dc.subject.emtreeAmisulprideen_US
dc.subject.emtreeBiperidenen_US
dc.subject.emtreeBornaprineen_US
dc.subject.emtreeGlimepirideen_US
dc.subject.emtreeHaloperidolen_US
dc.subject.emtreeLithiumen_US
dc.subject.emtreeMetforminen_US
dc.subject.emtreeQuetiapineen_US
dc.subject.emtreeValproic aciden_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeZiprasidoneen_US
dc.subject.emtreeZuclopenthixol decanoateen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCase reporten_US
dc.subject.emtreeDiabetes mellitusen_US
dc.subject.emtreeDiagnostic and statistical manual of mental disordersen_US
dc.subject.emtreeDisease exacerbationen_US
dc.subject.emtreeDrug blood levelen_US
dc.subject.emtreeDrug dose increaseen_US
dc.subject.emtreeDrug dose reductionen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug responseen_US
dc.subject.emtreeDrug substitutionen_US
dc.subject.emtreeDrug withdrawalen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreePsychosisen_US
dc.subject.emtreeQT prolongationen_US
dc.subject.emtreeSchizophreniaen_US
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
Kısa Öğe Kaydını Göster İstatistikler


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.